Ulcerative Colitis

Men who have sex with men were more than twice as likely to develop inflammatory bowel disease compared with men who have sex with women when engaging in “high-risk” sexual activity, according to research published in Gut.

Obefazimod improved moderate to severe ulcerative colitis compared with placebo in patients with documented nonresponse or intolerance to previous treatment, according to new data published in The Lancet Gastroenterology & Hepatology.

Adolescents and young adults with inflammatory bowel diseases are a growing demographic with more than 25% of patients diagnosed before age 16, according to research published in Inflammatory Bowel Diseases.

Use of biologics did not worsen stable SARS-CoV-2 infection in patients with inflammatory bowel disease if given within 2 weeks of virus detection, according to research published in Clinical Gastroenterology and Hepatology.

Individuals with severe childhood-onset inflammatory bowel disease, who underwent surgery or long-term inpatient care, had 16% lower occupational earnings from age 20 to 30 years compared with the general population, according to research.

The European Commission approved Rinvoq for the treatment of patients with moderate to severe ulcerative colitis who had an inadequate response, lost response or were intolerant to conventional therapy, according to an AbbVie press release.

Excessive intake of sugar-sweetened beverages may increase the risk for inflammatory bowel disease, according to research published in Alimentary Pharmacology and Therapeutics.

Hispanic patients treated with biologic agents for inflammatory bowel diseases face a greater risk for hospitalization, surgery and infections compared with non-Hispanic patients, according to a study in Clinical Gastroenterology and Hepatology.

Patients with inflammatory bowel disease were nine times more likely to develop depression, and their unaffected siblings twice as likely to develop depression, according to a study in the Journal of Gastroenterology and Hepatology.

In a Healio video exclusive, Remo Panaccione, MD, discusses results from long-term, pooled analyses of adult patients treated with ustekinumab for inflammatory bowel disease.